Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Senior VP - CCO | January 25, 2019 | January 29, 2019 |
| BIORA THERAPEUTICS, INC.BIOR · Entity 85047 | Director | June 05, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date January 25, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2019-01-28 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2019-01-25 · Exercise / conversion · Acquired 6,000 · Balance 6,000 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Row 2 · 2019-01-25 · Sale · Disposed 6,000 · Balance 0 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F2: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.50 to $9.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Row 3 · 2019-01-28 · Exercise / conversion · Acquired 4,000 · Balance 4,000 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Row 4 · 2019-01-28 · Sale · Disposed 4,000 · Balance 0 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F3: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.85 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Row 5 · 2019-01-28 · Exercise / conversion · Acquired 2,000 · Balance 2,000 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Row 6 · 2019-01-28 · Sale · Disposed 2,000 · Balance 0 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F5: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.90 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2026-05-23 | Direct | 85,427 |
Reported balance
After 2019-01-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-25 · Exercise / conversion · Disposed 6,000 · Balance 85,427 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2026-05-23 | Direct | 81,427 |
Reported balance
After 2019-01-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-01-28 · Exercise / conversion · Disposed 4,000 · Balance 81,427 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2026-05-23 | Direct | 79,427 |
Reported balance
After 2019-01-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-01-28 · Exercise / conversion · Disposed 2,000 · Balance 79,427 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.
F2: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.50 to $9.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.85 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018.
F5: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.90 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
BIORA THERAPEUTICS, INC.
Report date June 05, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,746 |
Reported balance
After 2024-06-05 transaction · row 1
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 12,500 · Balance 30,746 F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2034-06-05 | Direct | 12,500 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Grant · Acquired 12,500 · Balance 12,500 F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2024 Filed Jun 6, 2024 16:33 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000950170-24-069929 · ownership.xml · derivative · entry 2 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-05 F2 · derivative.exercise_date: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 16:33 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069929 · ownership.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,746 F1 · shares: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:06 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0000950170-23-028596 · ownership.xml · derivative · entry 2 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:06 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-028596 · ownership.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,246 F1 · shares: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:05 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Disposition to issuerSeries X Preferred Stock | 45 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000960 · doc4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. F2 · price: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:30 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 148,810 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-22-023090 · doc4.xml · derivative · entry 2 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,810 Underlying: Common Stock · 148,810 shares Expires 2032-06-15 F2 · deemedExecutionDate: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:30 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 96,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023090 · doc4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,672 F1 · shares: Represents 96,154 restricted stock units, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:07 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 51,724 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0000899243-21-024210 · doc4.xml · derivative · entry 2 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,724 Underlying: Common Stock · 51,724 shares Expires 2021-06-14 F2 · deemedExecutionDate: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 51,724 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:07 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantCommon Stock | 29,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-024210 · doc4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,518 F1 · shares: Represents 29,183 restricted stock units, which vest in full on the earlier of (1) June 14, 2022 or (2) the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · derivative · entry 9 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,427 Underlying: Common Stock · 2,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · derivative · entry 8 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,427 Underlying: Common Stock · 4,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 2,000 | $9.91 | $19,820.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · nonDerivative · entry 6 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F5 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.90 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 2,000 | $3.22 | $6,440.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · nonDerivative · entry 5 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 4,000 | $9.88 | $39,520.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · nonDerivative · entry 4 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F3 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.85 to $9.91. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 4,000 | $3.22 | $12,880.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · nonDerivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · derivative · entry 7 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,427 Underlying: Common Stock · 6,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 6,000 | $9.60 | $57,600.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.50 to $9.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 6,000 | $3.22 | $19,320.00 |
DisclosureSEC source: 0001127602-19-002873 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-19-002527 · form4.xml · derivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,427 Underlying: Common Stock · 2,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 2,000 | $9.40 | $18,800.00 |
DisclosureSEC source: 0001127602-19-002527 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 2,000 | $3.22 | $6,440.00 |
DisclosureSEC source: 0001127602-19-002527 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,046 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-19-002367 · form4.xml · derivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,427 Underlying: Common Stock · 3,046 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,046 | $9.27 | $28,236.42 |
DisclosureSEC source: 0001127602-19-002367 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.20 to $9.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,046 | $3.22 | $9,808.12 |
DisclosureSEC source: 0001127602-19-002367 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 954 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-19-002141 · form4.xml · derivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,473 Underlying: Common Stock · 954 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 954 | $9.20 | $8,776.80 |
DisclosureSEC source: 0001127602-19-002141 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 954 | $3.22 | $3,071.88 |
DisclosureSEC source: 0001127602-19-002141 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001127602-18-037177 · form4.xml · derivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2028-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-036067 · form4.xml · derivative · entry 6 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,427 Underlying: Common Stock · 2,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-036067 · form4.xml · derivative · entry 5 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,427 Underlying: Common Stock · 2,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 2,000 | $9.11 | $18,220.00 |
DisclosureSEC source: 0001127602-18-036067 · form4.xml · nonDerivative · entry 4 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F3 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.10 to $9.11. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 2,000 | $3.22 | $6,440.00 |
DisclosureSEC source: 0001127602-18-036067 · form4.xml · nonDerivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 2,000 | $9.01 | $18,020.00 |
DisclosureSEC source: 0001127602-18-036067 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.00 to $9.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 2,000 | $3.22 | $6,440.00 |
DisclosureSEC source: 0001127602-18-036067 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-034303 · form4.xml · derivative · entry 4 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,427 Underlying: Common Stock · 12,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 2,455 | $9.01 | $22,119.55 |
DisclosureSEC source: 0001127602-18-034303 · form4.xml · nonDerivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F3 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.00 to $9.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 12,000 | $9.06 | $108,720.00 |
DisclosureSEC source: 0001127602-18-034303 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,455 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.80 to $9.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 12,000 | $3.22 | $38,640.00 |
DisclosureSEC source: 0001127602-18-034303 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:51 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 9,127 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-034196 · form4.xml · derivative · entry 7 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,427 Underlying: Common Stock · 9,127 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:51 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 6,150 | $8.61 | $52,951.50 |
DisclosureSEC source: 0001127602-18-034196 · form4.xml · nonDerivative · entry 5 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,455 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F3 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.50 to $8.72. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:51 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 9,127 | $8.52 | $77,762.04 |
DisclosureSEC source: 0001127602-18-034196 · form4.xml · nonDerivative · entry 4 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,605 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.40 to $8.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:51 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 9,127 | $3.22 | $29,388.94 |
DisclosureSEC source: 0001127602-18-034196 · form4.xml · nonDerivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:51 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 193 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-034196 · form4.xml · derivative · entry 6 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,554 Underlying: Common Stock · 193 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:51 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 193 | $8.30 | $1,601.90 |
DisclosureSEC source: 0001127602-18-034196 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,605 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:51 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 193 | $3.22 | $621.46 |
DisclosureSEC source: 0001127602-18-034196 · form4.xml · nonDerivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 5,280 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032640 · form4.xml · derivative · entry 6 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,747 Underlying: Common Stock · 5,280 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,280 | $8.15 | $43,032.00 |
DisclosureSEC source: 0001127602-18-032640 · form4.xml · nonDerivative · entry 4 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,605 F1 · date: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.00 to $8.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,280 | $3.22 | $17,001.60 |
DisclosureSEC source: 0001127602-18-032640 · form4.xml · nonDerivative · entry 3 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-032640 · form4.xml · derivative · entry 5 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,027 Underlying: Common Stock · 300 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 300 | $8.00 | $2,400.00 |
DisclosureSEC source: 0001127602-18-032640 · form4.xml · nonDerivative · entry 2 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,605 F1 · date: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.